Preclinical studies suggest that malignant peripheral nerve sheath tumors (MPNSTs) in NF1 may respond well to combined therapy using all-trans retinoic acid (ATRA) and MEK inhibitors. This evidence concerns the gene MAP2K7 and neurofibromatosis type 1.